Patients who are assessed by a Health Care Worker and meet all the criteria below will be considered for home-based isolation and care:
- Laboratory confirmed COVID-19
- Asymptomatic patients or patients with mild symptoms of COVID-19
- Absence of comorbidities
- Access to a suitable space for home-based isolation and care
The findings of this well done randomized controlled trial indicate that in patients with COVID-19 pneumonia, that dexamethasone improves 28d mortality compared to placebo in patients requiring invasive mechanical ventilation (IMV) (NNT = 8.5) and those patients requiring oxygen therapy (NNT = 29). There was no benefit to patients not requiring oxygenation support and even a signal for harm. It is important to remember this is a preprint, preliminary report, which is better than a press release. At this time, in patients requiring any oxygen therapy, HFNC, NIV, IMV, or ECMO I would recommend dexamethasone until further evidence disproves this benefit.